About beta bionics inc - BBNX
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
BBNX At a Glance
Beta Bionics, Inc.
11 Hughes
Irvine, California 92618
| Phone | 1-949-427-7785 | Revenue | 100.25M | |
| Industry | Medical Specialties | Net Income | -73,200,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 53.939% | |
| Fiscal Year-end | 12 / 2026 | Employees | 423 | |
| View SEC Filings |
BBNX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 12.318 |
| Price to Book Ratio | 4.70 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -14.868 |
| Enterprise Value to Sales | 10.204 |
| Total Debt to Enterprise Value | 0.007 |
BBNX Efficiency
| Revenue/Employee | 237,000.00 |
| Income Per Employee | -173,049.645 |
| Receivables Turnover | 5.107 |
| Total Asset Turnover | 0.419 |
BBNX Liquidity
| Current Ratio | 8.663 |
| Quick Ratio | 7.961 |
| Cash Ratio | 7.089 |
BBNX Profitability
| Gross Margin | 55.398 |
| Operating Margin | -71.502 |
| Pretax Margin | -73.017 |
| Net Margin | -73.017 |
| Return on Assets | -30.603 |
| Return on Equity | -40.261 |
| Return on Total Capital | -24.821 |
| Return on Invested Capital | -39.07 |
BBNX Capital Structure
| Total Debt to Total Equity | 2.539 |
| Total Debt to Total Capital | 2.476 |
| Total Debt to Total Assets | 2.221 |
| Long-Term Debt to Equity | 1.865 |
| Long-Term Debt to Total Capital | 1.819 |